Trial Profile
A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary) ; Dexamethasone; Doxorubicin liposomal
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Janssen; Janssen Research & Development; Janssen-Cilag
- 21 Sep 2020 Results of subanalysis presented at the 45th European Society for Medical Oncology Congress
- 14 Sep 2020 According to a PharmaMar media release, subanalysis of this trial will be presented at the European Society of Medical Oncology (ESMO) Congress, which will be held virtually from 17th to 19th of Sep 2020.
- 24 Jul 2020 According to an European Medicines Agency media release, EMA has recommended that the use of Yondelis (trabectedin) in treating ovarian cancer remain unchanged following a review of this study.However, the study results will be included in the medicine product information to provide healthcare professionals with the most up-to-date information on the effects of Yondelis in patients with ovarian cancer.